Researchers conducted a retrospective analysis of data obtained from the Agency for Healthcare Research and Quality’s National Inpatient Sample between 2010 and 2014.
The study shows treatment costs for MRSA-related pneumonia were approximately $38,500 in 2014 versus $40,700-plus for methicillin-susceptible Staphylococcus aureus-related pneumonias.
Additionally, treatments costs for non-pneumonia hospitalizations related to staph infections were $14,792 for MRSA-related infections as compared to $15,578 for MSSA-related infections in 2014. The cost differences between MSSA-and MRSA-related pneumonia hospitalizations rose from 25.8 percent in 2010 to 31 percent in 2014.
“The lower costs for treating drug-resistant infections were a surprise,” said Trish Perl-DeLisle, MD, chief of infectious diseases at Dallas-based UT Southwestern Medical Center and a co-author of the study. “The findings are contrary to previous predictions and studies that suggested the treatment costs for drug-resistant infections would be greater.”
More articles on healthcare quality:
Physicians from shuttered California hospital allege care quality declined under HCCA control
Why nutrition matters: How Advocate Healthcare cut readmissions, LOS & costs
How reconsidering pricing strategy could help save more hepatitis C patients
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.